Notably, the role of IFI30 appears to be context‐dependent in various cancer types: in glioma, elevated IFI30 expression is associated with poor prognosis [12, 18], whereas in melanoma and diffuse large B‐cell lymphoma, it correlates with better survival outcomes [7, 13]. Here, IFI30 is linked to glioma.